UBS Oncology Impact Fund L.P.

Track

Insider profile

Performance

Overall performance
2.3
Performance over holding periods
2.3
30 days 90 days 120 days
Average return 15% 8.2% 15.1%
Success rate 74% 68% 82%
Transactions
3 67% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
UBS Oncology Impact Fund L.P.'s trades of Werewolf Therapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-06 2026-07-06
PrS Proposed sale
86,909
136.30
US$1,628,163 		86,909 136.30 US$1,628,163
2026-06-29 2026-06-29
PrS Proposed sale
18,611
84.84
US$4,721,425 		18,611 84.84 US$4,721,425
2026-05-28 2026-05-28
PrS Proposed sale
8,424
36.26
US$4,295,767 		8,424 36.26 US$4,295,767
2026-05-18 2026-05-18
PrS Proposed sale
240,280
0.52
US$123,768 		240,280 0.52 US$123,768
2026-05-11 2026-05-11
PrS Proposed sale
69,904
0.68
US$47,535 		69,904 0.68 US$47,535
2026-05-01 2026-05-01
PrS Proposed sale
300,821
0.72
US$216,471 		300,821 0.72 US$216,471
2026-04-29 2026-04-29
PrS Proposed sale
107,652
0.74
US$79,662 		107,652 0.74 US$79,662
2026-04-27 2026-04-27
PrS Proposed sale
107,652
0.81
US$87,521 		107,652 0.81 US$87,521
2026-01-06 2026-01-06
PrS Proposed sale
164,126
0.64
US$105,763 		164,126 0.64 US$105,763
2025-12-29 2025-12-29
PrS Proposed sale
107,463
0.65
US$70,313 		107,463 0.65 US$70,313
2025-12-22 2025-12-22
PrS Proposed sale
107,463
0.69
US$73,806 		107,463 0.69 US$73,806
2025-12-10 2025-12-10
PrS Proposed sale
73,195
1.01
US$73,927 		73,195 1.01 US$73,927
2025-12-03 2025-12-03
PrS Proposed sale
107,463
0.86
US$92,418 		107,463 0.86 US$92,418
2025-11-24 2025-11-24
PrS Proposed sale
107,463
0.87
US$93,837 		107,463 0.87 US$93,837
2025-11-17 2025-11-17
PrS Proposed sale
107,463
0.92
US$98,673 		107,463 0.92 US$98,673
2025-11-10 2025-11-10
PrS Proposed sale
107,463
1.15
US$123,582 		107,463 1.15 US$123,582
2025-11-04 2025-11-04
PrS Proposed sale
107,463
1.31
US$140,777 		107,463 1.31 US$140,777
2025-10-30 2025-10-30
PrS Proposed sale
107,463
1.56
US$167,642 		107,463 1.56 US$167,642
2025-10-27 2025-10-27
PrS Proposed sale
107,463
1.77
US$190,210 		107,463 1.77 US$190,210
2021-09-13 2021-09-13
PlS Planned sale
3,595 -0.0%
29.10
US$104,614 		3,595 -0.0% 29.10 US$104,614
2021-09-13 2021-09-10
PlS Planned sale
5,931 -0.1%
29.04
US$172,236 		5,931 -0.1% 29.04 US$172,236
2021-09-13 2021-09-09
PlS Planned sale
13,727 -0.2%
29.35
US$402,887 		13,727 -0.2% 29.35 US$402,887
2021-01-14 2021-01-12
B Purchase
300,000 +3.9%
21.00
US$6,300,000 		300,000 +3.9% 21.00 US$6,300,000
2020-10-08 2020-10-06
US Oncorus Inc (ONCR)
B Purchase
151,224 +6.8%
15.00
US$2,268,360 		151,224 +6.8% 15.00 US$2,268,360
2019-02-21 2019-02-19
B Purchase
666,667 +24.7%
15.00
US$10,000,005 		666,667 +24.7% 15.00 US$10,000,005
2019-02-14 2019-02-12
B Purchase
250,000 +6.9%
14.00
US$3,500,000 		250,000 +6.9% 14.00 US$3,500,000
2019-02-14 2019-02-12
S Sale
447 -0.0%
14.00
US$6,258 		447 -0.0% 14.00 US$6,258